A phase II clinical study on relapsed malignant gliomas treated with electro-hyperthermia
/in Glioblastoma, Hyperthermia, International PublicationsCombined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid
/in Brain Tumors in Children, Glioblastoma, International Publications, Newcastle Disease VirusExpression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy
/in Glioblastoma, International PublicationsInduction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells
/in Glioblastoma, International PublicationsCellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy
/in Glioblastoma, International PublicationsDendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice
/in Glioblastoma, International PublicationsSensitization of malignant glioma to chemotherapy through dendritic cell vaccination
/in Glioblastoma, International PublicationsEnhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12
/in Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer